Cargando…

Hepatocellular Carcinoma in the COVID‐19 Era: Primetime for Stereotactic Body Radiotherapy and a Lesson for the Future?

The COVID‐19 pandemic has presented an opportunity to evaluate current practices in cancer care. This letter to the editor focuses on one example, making the case for stereotactic body radiotherapy in Hepatocellular Carcinoma.

Detalles Bibliográficos
Autores principales:	Scorsetti, Marta, Goodman, Karyn A., Seong, Jinsil, Loi, Mauro, Huguet, Florence, Dawson, Laura A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Letters to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307056/ https://www.ncbi.nlm.nih.gov/pubmed/32525607 http://dx.doi.org/10.1634/theoncologist.2020-0416

Ejemplares similares

Recommendations for the use of radiation therapy in managing patients with gastrointestinal malignancies in the era of COVID-19()
por: Tchelebi, Leila T., et al.
Publicado: (2020)

Stereotactic Body Radiotherapy: Does It Have a Role in Management of Hepatocellular Carcinoma?
por: Choi, Seo Hee, et al.
Publicado: (2018)

Primetime for Learning Genes
por: Keifer, Joyce
Publicado: (2017)

Commentary: Preoperative Screening CT: Not Ready for Primetime in The COVID-19 Era
por: Porterie, Jean, et al.
Publicado: (2021)

Phase I dose-escalation study of helical intensity-modulated radiotherapy-based stereotactic body radiotherapy for hepatocellular carcinoma
por: Kim, Jun Won, et al.
Publicado: (2016)

The Shock Index: is it ready for primetime?
por: Moffat, Brad, et al.
Publicado: (2013)

EUS Gastroenterostomy: Primetime for All?
por: Canakis, Andrew, et al.
Publicado: (2023)

Challenge and Hope in Radiotherapy of Hepatocellular Carcinoma
por: Seong, Jinsil
Publicado: (2009)

Plk1 in Asthma: Ready for Primetime?
por: Tam, John Kit Chung, et al.
Publicado: (2021)

Vertebral compression fracture after stereotactic ablative radiotherapy in patients with oligometastatic bone lesions from hepatocellular carcinoma
por: Hyung Kim, Tae, et al.
Publicado: (2023)

eIF4A inhibition: ready for primetime?
por: Cunningham, Tyler A., et al.
Publicado: (2018)

Strategic application of radiotherapy for hepatocellular carcinoma
por: Choi, Seo Hee, et al.
Publicado: (2018)

Stereotactic Radiotherapy for Ultra-Central Lung Oligometastases in Non-Small-Cell Lung Cancer
por: Loi, Mauro, et al.
Publicado: (2020)

Stereotactic Ablative Radiotherapy for Oligometastatic Hepatocellular Carcinoma: A Multi-Institutional Retrospective Study (KROG 20-04)
por: Kim, Tae Hyung, et al.
Publicado: (2022)

The Optimal Selection of Radiotherapy Treatment for Hepatocellular Carcinoma
por: Lee, Ik Jae, et al.
Publicado: (2012)

Stereotactic body radiation therapy and radiofrequency ablation in patients with hepatocellular carcinoma: not a rival but a partner for the cure
por: Kim, Nalee, et al.
Publicado: (2022)

Carbon Ion Radiotherapy in the Treatment of Hepatocellular Carcinoma
por: Byun, Hwa Kyung, et al.
Publicado: (2023)

Application of radiotherapy for hepatocellular carcinoma in current clinical practice guidelines
por: Rim, Chai Hong, et al.
Publicado: (2016)

Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma
por: Lee, Byung Min, et al.
Publicado: (2021)

Manipulation of the intestinal microbiome-a slow journey to primetime
por: Kriger-Sharabi, Ofra, et al.
Publicado: (2023)

Stereotactic Radiotherapy for Parasagittal and Parafalcine Meningiomas: Patient Selection and Special Considerations
por: Pinzi, V, et al.
Publicado: (2019)

Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?
por: Kikuchi, Robin, et al.
Publicado: (2020)

The Use of Breath Analysis in the Management of Lung Cancer: Is It Ready for Primetime?
por: Keogh, Rachel J., et al.
Publicado: (2022)

Technical Aspects and Clinical Outcomes of Robotic Ureteroscopy: Is It Ready for Primetime?
por: Sinha, Mriganka Mani, et al.
Publicado: (2023)

Predictive Factors of Palliative Radiotherapy Response and Survival in Patients with Spinal Metastases from Hepatocellular Carcinoma
por: Choi, Chihwan, et al.
Publicado: (2015)

Skull Base Metastasis from Hepatocellular Carcinoma: Clinical Presentation and Efficacy of Radiotherapy
por: Kim, Kangpyo, et al.
Publicado: (2022)

Survival and Prognostic Factors of Ultra-Central Tumors Treated with Stereotactic Body Radiotherapy
por: Salvestrini, Viola, et al.
Publicado: (2022)

Primetime learning: collaborative and technology-enhanced studying with genuine teacher presence
por: Koskinen, Pekka, et al.
Publicado: (2018)

Multi-analyte analysis of cytokines that predict outcomes in patients with hepatocellular carcinoma treated with radiotherapy
por: Cha, Hyejung, et al.
Publicado: (2017)

Long-term survival after multimodal treatment involving radiotherapy for huge hepatocellular carcinoma with oligometastasis: a case report
por: Lee, Byung Min, et al.
Publicado: (2021)

Feasibility of Sorafenib Combined with Local Radiotherapy in Advanced Hepatocellular Carcinoma
por: Cha, Jihye, et al.
Publicado: (2013)

The Use of Magnetic Resonance Imaging in the Prostate Cancer Primary Diagnostic Pathway: Is It Ready for Primetime?
por: Sathianathen, Niranjan J., et al.
Publicado: (2018)

Stereotactic ablative radiotherapy for oligometastatic prostate cancer
por: Gallizia, Elena, et al.
Publicado: (2022)

Not Ready for Primetime: Challenges of Antenatal Ultrasound in Low- and Middle-Income Country Settings
Publicado: (2017)

Examining Diversity: a Content Analysis of Cancer Depictions on Primetime Scripted Television
por: Kim, Grace
Publicado: (2021)

Transapical mitral valve repair procedures: Primetime for microinvasive mitral valve surgery
por: D'Onofrio, Augusto, et al.
Publicado: (2021)

Efficacy of Stereotactic Body Radiotherapy in Patients With Hepatocellular Carcinoma Not Suitable for Transarterial Chemoembolization (HERACLES: HEpatocellular Carcinoma Stereotactic RAdiotherapy CLinical Efficacy Study)
por: Brunner, Thomas B., et al.
Publicado: (2021)

Favorable response of hepatocellular carcinoma with portal vein tumor thrombosis after radiotherapy combined with atezolizumab plus bevacizumab
por: Kim, Yong Tae, et al.
Publicado: (2023)

Plasma Cell-Free DNA as a Predictive Marker after Radiotherapy for Hepatocellular Carcinoma
por: Park, Sangjoon, et al.
Publicado: (2018)

Stereotactic radiotherapy for prostate cancer: A review and future directions
por: Syed, Yusef A, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_rqlhss4d8ctgedjj6br9vugakm